{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:21:04Z","timestamp":1776788464107,"version":"3.51.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,16]]},"DOI":"10.7759\/cureus.103700","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:33:06Z","timestamp":1771237986000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Evaluation of a Trastuzumab Emtansine Biosimilar (Ujvira\u00ae) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer"],"prefix":"10.7759","author":[{"given":"MV","family":"Chandrakanth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupam","family":"Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minakshi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaustav","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nibedita","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritam K","family":"Sardar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparajita","family":"Sadhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moinak","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhabrata","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himadri","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipulkumar","family":"Thummar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_111_18","article-title":"Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer","volume":"7","author":"Bahl A","year":"2018","unstructured":"Bahl A, Singh R, Wadhwa J, et al.. Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. South Asian J Cancer. 2018, 7:102-5. 10.4103\/sajc.sajc_111_18","journal-title":"South Asian J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop IE","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, et al.. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017, 18:743-54. 10.1016\/S1470-2045(17)30313-3","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606)","volume":"31","author":"Montemurro F","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, et al.. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Ann Oncol. 2020, 31:1350-8. 10.1016\/j.annonc.2020.06.020","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.11.006","article-title":"Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) with the Kadcyla (Trastuzumab Emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India","volume":"22","author":"Chiradoni Thungappa S","year":"2022","unstructured":"Chiradoni Thungappa S, Maksud T, Raut N, Nagarkar R, Batra U, Kumar S, Parmar D. Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) with the Kadcyla (Trastuzumab Emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India. Clin Breast Cancer. 2022, 22:300-7. 10.1016\/j.clbc.2021.11.006","journal-title":"Clin Breast Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde L","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018, 35:1763-74. 10.1007\/s12325-018-0805-y","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63589","article-title":"A case report on trastuzumab emtansine (T-DM1) in a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases: long-term treatment and survival","volume":"16","author":"Doshi V","year":"2024","unstructured":"Doshi V, Thummar V, Mehta P. A case report on trastuzumab emtansine (T-DM1) in a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases: long-term treatment and survival. Cureus. 2024, 16:e63589. 10.7759\/cureus.63589","journal-title":"Cureus"},{"key":"ref8","unstructured":"ECOG Performance Status Scale - ECOG-ACRIN Cancer Research Group. Accessed. January 6, 2026: http:\/\/acrin.org\/resources\/ecog-performance-status\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn S","year":"2020","unstructured":"Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020, 54:34-44. 10.4132\/jptm.2019.11.03","journal-title":"J Pathol Transl Med"},{"key":"ref10","unstructured":"CTEP Trial Development and Conduct - NCI. Accessed. Accessed. January 6, 2026: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development.."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97923-2","article-title":"Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients","volume":"15","author":"Gupta A","year":"2025","unstructured":"Gupta A, Sansar B, Mishra BK, et al.. Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients. Sci Rep. 2025, 15:18669. 10.1038\/s41598-025-97923-2","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76061","article-title":"Evaluation of the safety and efficacy of trastuzumab emtansine (T-DM1) biosimilar in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: findings from a single-center retrospective analysis in India","volume":"16","author":"Patel K","year":"2024","unstructured":"Patel K, Thummar V, Mehta P. Evaluation of the safety and efficacy of trastuzumab emtansine (T-DM1) biosimilar in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: findings from a single-center retrospective analysis in India. Cureus. 2024, 16:e76061. 10.7759\/cureus.76061","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.18231\/j.joapr.2024.12.2.35.41","article-title":"A single centre, real world experience of T-DM1 in the treatment of HER2-positive metastatic breast cancer patients in India","volume":"12","author":"Andra VV","year":"2024","unstructured":"Andra VV, Vamsy M, Dayal M, Shinkar P. A single centre, real world experience of T-DM1 in the treatment of HER2-positive metastatic breast cancer patients in India. J Appl Pharm Res. 2024, 12:35-41. 10.18231\/j.joapr.2024.12.2.35.41","journal-title":"J Appl Pharm Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.30683\/1929-2279.2025.14.13","article-title":"Real-world clinical outcomes of Ujvira\u00ae (trastuzumab emtansine biosimilar) in HER2-positive breast cancer: a retrospective observational study in Indian patients","volume":"14","author":"Karuvandan N","year":"2025","unstructured":"Karuvandan N, Ventrapati P. Real-world clinical outcomes of Ujvira\u00ae (trastuzumab emtansine biosimilar) in HER2-positive breast cancer: a retrospective observational study in Indian patients. J Can Res Updates. 2025, 14:114-20. 10.30683\/1929-2279.2025.14.13","journal-title":"J Can Res Updates"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67047","article-title":"Long-term success with a TDM-1 biosimilar in recurrent HER2-positive breast cancer with multisite metastases: a comprehensive case study","volume":"16","author":"Biswas G","year":"2024","unstructured":"Biswas G, Subudhi GC, Biswas S, Das B. Long-term success with a TDM-1 biosimilar in recurrent HER2-positive breast cancer with multisite metastases: a comprehensive case study. Cureus. 2024, 16:e67047. 10.7759\/cureus.67047","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451128-real-world-evaluation-of-a-trastuzumab-emtansine-biosimilar-ujvira-in-human-epidermal-growth-factor-receptor-2-her2-positive-metastatic-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:33:06Z","timestamp":1771237986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451128-real-world-evaluation-of-a-trastuzumab-emtansine-biosimilar-ujvira-in-human-epidermal-growth-factor-receptor-2-her2-positive-metastatic-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.103700","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}